Product apis-protein-tyrosine-kinase

Home > products > apis> protein-tyrosine-kinase

Catalog	name	Description	price
R-C-1950	STK321130 CAS:923562-23-6	STK321130(FLT3-IN-2)is potent FLT3 inhibitor.	price>
R-C-1974	BMS-986142 CAS ：1643368-58-4	BMS-986142 is a potent,selective,reversible BTK inhibitor.BMS-986142 shows BTK IC50=0.5nM;human WB IC50=90 nM.In molecule of BMS-986142,two atropisomeric centers were rotationally locked to provide a single,stable atropisomer,resulting in enhanced potency and selectivity as well as a reduction in safety liabilities.With significantly enhanced potency and selectivity, excellent in vivo properties and efficacy,and a very desirable tolerability and safety profile,BMS-986142 was advanced into clinical studies.	price>
R-C-1985	Alflutinib (AST2818) mesylate CAS：2130958-55-1	Alflutinib(AST2818)mesylate is a third-generation epidermal growth factor receptor(EGFR)inhibitor that inhibits both EGFR-sensitive mutations and T790M mutations.Alflutinib(AST2818),primarily metabolized by CYP3A4,is also a potent CYP3A4 inducer with EC50 of 0.25μM.	price>
R-C-1998	Sitravatinib CAS: 1123837-84-2	Sitravatinib(MGCD516)is an orally bioavailable receptor tyrosine kinase (RTK)inhibitor with IC50s of 1.5nM,2nM,2nM,5nM,6nM,6nM,8nM,0.5nM,2nM,5nM,and 9 nM for Axl,MER,VEGFR3,VEGFR2,VEGFR1,KIT,FLT3,DDR2,DDR1,TRKA,TRKB,respectively. Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment.	price>
R-C-2017	BMS-986165 CAS：1609392-27-9	BMS-986165 is a Highly Potent and Selective Allosteric Inhibitor of TYK2.BMS-986165 Blocks Il-12,IL-23 and type I Interferon Signaling and Provides for Robust Efficacy in Preclinical Models of Inflammatory Bowel Disease.	price>
R-C-2032	AZD-3463 CAS：1356962-20-3	AZD3463 is a novel orally bioavailable ALK inhibitor with Ki of 0.75nM, which also inhibits IGF1R with equivalent potency.AZD3463 suppresses cell viability by inducing both cell apoptosis and autophagy.	price>
R-C-2040	Mobocertinib (TAK788) CAS：1847461-43-1	Mobocertinib(TAK788,AP32788)an investigational TKI,is a potent, selective preclinical inhibitor of epidermal growth factor receptor (EGFR)and HER2 mutations.Mobocertinib(TAK788)is an antineoplastic agent.	price>
R-C-2053	ALW-II-41-27 CAS:1186206-79-0	ALW-II-41-27 is a Eph receptor tyrosine kinase inhibitor.pharmacologic inhibition of EPHA2 by the small-molecule inhibitor ALW-II-41-27 decreased both survival and proliferation of erlotinib-resistant tumor cells and inhibited tumor growth in vivo.ALW-II-41-27 was also effective in decreasing viability of cells with acquired resistance to the third-generation EGFR TKI AZD9291. Collectively,these data define a role for EPHA2 in the maintenance of cell survival of TKI-resistant,EGFR-mutant lung cancer and indicate that EPHA2 may serve as a useful therapeutic target in TKI-resistant tumors.	price>
R-C-2057	Ki20227 CAS:623142-96-1	Ki20227 is an orally active and highly selective inhibitor of c-Fms tyrosine kinase(CSF1R)with IC50 of 2 nM,12nM,451 nM and 217 nM for c-Fms,vascular endothelial growth factor receptor-2(KDR/VEGFR-2),stem cell factor receptor(c-Kit),and platelet-derived growth factor receptor beta(PDGFRβ).	price>
R-C-2061	Glumetinib CAS：1642581-63-2	Glumetinib(SCC244)is a potent and highly selective c-Met inhibitor with an IC50 of 0.42±0.02 nmol/L.Glumetinib has greater than 2,400-fold selectivity for c-Met over those 312 kinases evaluated,including the c-Met family member RON and highly homologous kinases Axl,Mer,and TyrO3.	price>

...